Wuxi International Life Science Innovation Campus (I-Campus) announces its full operation on April 27. [Photo/WeChat account: wuxifabu2013]
Wuxi International Life Science Innovation Campus (I-Campus) was officially put into operation on April 27, with 10 enterprises starting business there.
The I-Campus was developed by pharmaceutical giant AstraZeneca, the Wuxi government and the government of the Wuxi National Hi-Tech District.
During the opening ceremony, I-Campus and its strategic partner, the Australian Trade and Investment Commission, signed an online agreement and announced that they will work together to promote the exchange and interaction of Chinese and Australian life science companies.
Bao Di, the general manager of Greater China at the Australian Trade and Investment Commission, said that the importance of innovation and cooperation between the health sector and enterprises are being highlighted during the COVID-19 epidemic. He said he believes that the cooperation could help both sides to further expand cooperation areas and make contributions to patients worldwide.
Chris Wood, British consul-general in Shanghai, spoke highly of the cooperation Wuxi and Britain have exercised in the fight against the COVID-19 epidemic. He said the first business meeting he had participated in after the Chinese New Year was with Wuxi officials. He is bullish on the development of I-Campus, which is expected to play an important role in deepening Sino-UK cooperation.
The I-Campus deal was signed during last year's Boao Forum for Asia and launched in September. It represents another attempt by AstraZeneca to build an incubation platform for early research and development, the industrialization of research findings, the display of intelligent products, and the development of professional services in the life sciences sector.
According to the company, this platform covers four areas in the pharmaceutical industry: drugs, devices, diagnosis and digital.
